Utidelone plus Capecitabine for residual triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- Your breast cancer is triple-negative (estrogen, progesterone, and HER2 negative).
- You had chemotherapy before your surgery but some cancer remained (either in the breast or nearby lymph nodes).
- Your previous chemo included drugs like anthracycline or taxane.
- You are in generally good health, with normal blood, kidney, and liver function.
- You have no other active cancers, serious heart or lung problems, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
This trial tests if adding UTD2 to capecitabine works better than capecitabine alone for triple-negative breast cancer that didn't completely disappear after chemo. It's for patients who had surgery and are at risk of cancer coming back.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This Phase 3 study compares two chemotherapy combinations to treat HER2-negative breast cancer that has spread or is locally advanced. It aims to find which plan works better and has an acceptable side-effect profile for people who have had prior taxane treatment (in earlier-stage settings).
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.